Home » Stocks » KMPH

KemPharm, Inc. (KMPH)

Stock Price: $16.71 USD 7.28 (77.20%)
Updated Mar 3, 2021 9:53 AM EST - Market closed
Market Cap 178.89M
Revenue (ttm) 12.30M
Net Income (ttm) -13.94M
Shares Out 4.43M
EPS (ttm) -4.14
PE Ratio n/a
Forward PE 2.09
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $16.71
Previous Close $9.43
Change ($) 7.28
Change (%) 77.20%
Day's Open 15.50
Day's Range 15.00 - 18.12
Day's Volume 26,393,220
52-Week Range 0.18 - 18.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 4 hours ago

The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity di...

GlobeNewsWire - 10 hours ago

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

Financial Restructuring and Nasdaq Re-Listing Process Completed

GlobeNewsWire - 1 month ago

Combination of Oral and Poster Presentations Scheduled for January 15, 2021

GlobeNewsWire - 1 month ago

CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today a...

GlobeNewsWire - 1 month ago

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021

GlobeNewsWire - 2 months ago

CELEBRATION, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today an...

GlobeNewsWire - 2 months ago

CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today an...

GlobeNewsWire - 3 months ago

CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today an...

GlobeNewsWire - 3 months ago

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

GlobeNewsWire - 3 months ago

IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline , Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH)

GlobeNewsWire - 3 months ago

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

Seeking Alpha - 4 months ago

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET

GlobeNewsWire - 4 months ago

Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020, 8:00 a.m. ET

GlobeNewsWire - 4 months ago

CELEBRATION, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today an...

GlobeNewsWire - 4 months ago

New agreement provides additional revenue potentially through Q1 2022

Zacks Investment Research - 5 months ago

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

Other stocks mentioned: ALDX, NERV, SAVA
GlobeNewsWire - 5 months ago

CELEBRATION, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of ...

GlobeNewsWire - 5 months ago

Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment

GlobeNewsWire - 6 months ago

Presentations to Highlight Corporate, Regulatory and Pipeline Advancements Presentations to Highlight Corporate, Regulatory and Pipeline Advancements

GlobeNewsWire - 6 months ago

CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...

Seeking Alpha - 6 months ago

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET Conference Call and Live Audio Webcast with Slide Presentation Scheduled f...

GlobeNewsWire - 7 months ago

New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037

GlobeNewsWire - 8 months ago

CELEBRATION, Fla., June 18, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...

Forbes - 8 months ago

We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.

Other stocks mentioned: COCP, ECOR, INSE
GlobeNewsWire - 9 months ago

FDA Sets PDUFA Date of March 2, 2021

Zacks Investment Research - 9 months ago

KemPharma (KMPH) delivered earnings and revenue surprises of -1100.00% and -63.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 9 months ago

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET

GlobeNewsWire - 9 months ago

Corium, GPC’s portfolio company, to lead all commercialization activities for KP415

GlobeNewsWire - 1 year ago

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products

Zacks Investment Research - 1 year ago

KemPharma (KMPH) delivered earnings and revenue surprises of -28.57% and -62.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today

GlobeNewsWire - 1 year ago

Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date

Seeking Alpha - 1 year ago

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink

GlobeNewsWire - 1 year ago

CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, anno...

GlobeNewsWire - 1 year ago

CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, anno...

GlobeNewsWire - 1 year ago

CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...

GlobeNewsWire - 1 year ago

Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales

Zacks Investment Research - 1 year ago

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

KemPharm on Wednesday gave a presentation on its Apadaz commercialization progress, which is fairly exciting.

About KMPH

KemPharm, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ.... [Read more...]

Industry
Biotechnology
IPO Date
Apr 16, 2015
CEO
Travis Mickle
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
KMPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for KemPharm is 26.00, which is an increase of 55.60% from the latest price.

Price Target
$26.00
(55.60% upside)